DAPA-RWE: a retrospective multicenter study comparing dapagliflozin and sitagliptin in patients with Type 2 diabetes treated under routine clinical practice in Spain

Conclusion: DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.PMID:33955233 | DOI:10.2217/cer-2020-0264
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Source Type: research